文献速递前列腺癌

根治性前列腺切除术中应用NeuroSAFE可提高保留神经手术率且不影响肿瘤学结局

NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome.
PubMed 文献 · BJU Int · 2022-06-05

该研究纳入2016年1月至2020年12月接受机器人辅助根治性前列腺切除术的1756例前列腺癌患者,其中959例(55%)术中行NeuroSAFE,797例(45%)未行(对照组)。NeuroSAFE使pT2期(93% vs 76%)和pT3期(83% vs 55%)的保留神经手术率均提高,pT3期切缘阳性率从51%降至42%,且生化复发无生存更好(HR 0.62)。

要点

  • NeuroSAFE使pT2期保留神经手术率93% vs 对照组76%(P<0.001)。
  • NeuroSAFE使pT3期保留神经手术率83% vs 对照组55%(P<0.001)。
  • NeuroSAFE组生化复发无生存优于对照组(HR 0.62,95%CI 0.45-0.84;P=0.002)。

核心结论

  • NeuroSAFE可增加单侧和双侧保留神经手术,且不负面影响手术切缘状态和生化复发。

研究设计与样本

  • 2016年1月至2020年12月,1756例前列腺癌患者接受机器人辅助根治性前列腺切除术,其中959例(55%)行NeuroSAFE,797例(45%)未行(对照组)。
  • NeuroSAFE显示切缘有肿瘤时行二次切除。
  • 采用逻辑回归分析NeuroSAFE对保留神经手术和切缘阳性状态的影响,Cox回归识别生化复发无生存的预测因素。

主要发现

  • NeuroSAFE组患者肿瘤分级(P<0.001)和临床分期(P<0.001)高于对照组。
  • NeuroSAFE使pT2期保留神经手术率93% vs 对照组76%(P<0.001),pT3期83% vs 对照组55%(P<0.001)。
  • 校正分析中,NeuroSAFE使单侧保留神经手术更频繁(OR 3.90,95%CI 2.90-5.30;P<0.001),双侧也更频繁(OR 5.22,95%CI 3.90-6.98;P<0.001)。
  • pT3期患者切缘阳性率从51%降至42%(P=0.031),但NeuroSAFE并非整个队列切缘阳性状态的独立预测因素(OR 0.85,95%CI 0.68-1.06;P=0.2)。
  • NeuroSAFE组生化复发无生存优于对照组(HR 0.62,95%CI 0.45-0.84;P=0.002)。

临床怎么用

  • NeuroSAFE可在临床实践中用于术中决策,以增加单侧和双侧保留神经手术而不负面影响手术切缘状态和生化复发。

局限性

  • 本研究受限于与历史队列比较且缺乏功能结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the impact of intra-operative neurovascular structure-adjacent frozen-section examination (NeuroSAFE) on the rate of nerve-sparing surgery (NSS) and oncological outcome in a large radical prostatectomy (RP) cohort. PATIENTS AND METHODS: Between January 2016 and December 2020, 1756 prostate cancer patients underwent robot-assisted RP, of whom 959 (55%) underwent this with NeuroSAFE and 797 (45%) without (control cohort). In cases where NeuroSAFE showed tumour in the margin, a secondary resection was performed. The effect of NeuroSAFE on NSS and positive surgical margin (PSM) status was analysed using logistic regression. Cox regression was used to identify predictors of biochemical recurrence-free survival (BCRFS). RESULTS AND LIMITATIONS: Patients in the NeuroSAFE cohort had a higher tumour grade (P < 0.001) and clinical stage (P < 0.001) than those in the control cohort. NeuroSAFE enabled more frequent NSS for both pT2 (93% vs 76%; P < 0.001) and pT3 disease (83% vs 55%; P < 0.001). In adjusted analysis, NeuroSAFE resulted in more frequent unilateral (odds ratio [OR] 3.90, 95% confidence interval (CI) 2.90-5.30; P < 0.001) and bilateral (OR 5.22, 95% CI 3.90-6.98; P < 0.001) NSS. While the PSM rate decreased from 51% to 42% in patients with pT3 stage disease (P = 0.031), NeuroSAFE was not an independent predictor of PSM status (OR 0.85, 95% CI 0.68-1.06; P = 0.2) in the entire cohort. Patients who underwent NeuroSAFE had better BCRFS compared to the control cohort (hazard ratio 0.62, 95% CI 0.45-0.84; P = 0.002). This study is limited by its comparison with a historical cohort and lack of functional outcomes. CONCLUSIONS: NeuroSAFE enables more unilateral and bilateral NSS without negatively affecting surgical margin status and biochemical recurrence. This validation study provides a comprehensive overview of the implementation, evaluation and intra-operative decision making associated with NeuroSAFE in clinical practice.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. van der Slot MA, den Bakker MA, Tan TSC, et al. NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome. BJU Int. 2022. PMID: 35536200. doi:10.1111/bju.15771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。